Policy & Regulation
Harbour BioMed and Sinopharm establish innovation R&D consortium
27 July 2026 - Biopharmaceutical company Harbour BioMed (HKEX: 02142) declared on Monday that it has entered into a strategic collaboration with China National Pharmaceutical Group Co Ltd (Sinopharm) ...
argenx agrees to acquire Forte Biosciences for USD2.2bn to add anti-CD122 antibody FB102
27 July 2026 - Immunology innovation company argenx (Euronext & Nasdaq: ARGX) disclosed on Monday that it has entered into a definitive agreement to acquire biopharmaceutical company Forte Bioscie...
AstraZeneca reports positive Phase III survival results for Sone-Ve in advanced gastric cancers
27 July 2026 - Biopharmaceutical company AstraZeneca PLC (LSE: AZN) (STO: AZN) (NYSE: AZN) on Monday reported positive high-level results from the Phase III CLARITY-Gastric01 trial, with sonesitatug v...
Faron reports encouraging first overall survival data from BEXMAB frontline HR-MDS trial
27 July 2026 - Biopharmaceutical company Faron Pharmaceuticals Ltd (AIM: FARN) (First North: FARON) on Monday reported its first overall survival data from treatment-naïve higher-risk myelodyspla...
NewAmsterdam Pharma and Menarini Group report positive CHMP opinion for obicetrapib monotherapy and obicetrapib/ezetimibe combination
27 July 2026 - Late-stage biopharmaceutical company NewAmsterdam Pharma Company N.V. (Nasdaq:NAMS) and its partner Menarini Group announced on Friday that the Committee for Medicinal Products for Huma...
CHMP backs Gilead's Trodelvy-Keytruda combination for first-line metastatic triple-negative breast cancer
24 July 2026 - Biopharmaceutical company Gilead Sciences Inc (Nasdaq:GILD) announced on Friday that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recom...